Key Points
A Fragmented Landscape
Europe’s cannabis policies are evolving at different speeds, creating mismatched rules for patients and businesses.
Supply Chains Cross Borders
A product’s journey can span several countries, each with its own production, pharmaceutical, and import requirements.
Coordination Matters
Kardos argues that policy evaluation must examine how national systems interact across borders.
In This Article
A German citizen wants to bring prescribed medical cannabis into Hungary, but has doubts. A Hungarian CBD producer may find that part of the production process is easier to carry out in Czechia than at home. Can these situations be understood through national laws alone?
As a drug policy expert at the Hungarian Civil Liberties Union, I often encounter similar questions through our legal aid service. This highlights a specific issue in Europe: what happens when different national cannabis laws come into contact across borders? This is not a trivial question in an international community where people, goods, and businesses routinely cross borders every day.
Europe’s Fragmented Cannabis Landscape
The 2026 report from the European Union Drugs Agency (EUDA) highlights that cannabis policies in Europe are evolving at varying rates and in different directions. Germany, Malta and Spain have established different frameworks for adult-use cannabis; Luxembourg and Czechia have introduced limited home cultivation, while the Netherlands is testing regulated cannabis supply. At the same time, other countries maintain much more restrictive approaches.
Slovakia, for example, classified CBD as a banned substance in the same risk category as heroin until May 2021. Meanwhile, Hungary maintains that cannabis has no recognized medical values, treating it on par with the most dangerous drugs, despite a 2026 ruling against them by the European Court of Justice.
These differences may lead to situations in which people, products and businesses move between legal environments that were not designed to work together. For patients, determining if a prescription from their home country is recognized abroad can be complicated. Recreational users may also be unsure whether they’re allowed to bring products across borders.
When Cannabis Products Cross Borders
International businesses need to understand that a product legally sold in one European country may have different requirements in another. For instance, a medical cannabis manufacturer may source materials from one country, process them in another, and provide treatment to patients in yet another.
The European Court of Justice addressed a similar issue in the 2020 Kanavape case. French authorities carried out legal action against distributors of a CBD product that was lawfully manufactured in Czechia. French laws permitted hemp production and distribution only from specific parts of the plant, while the CBD was derived from the entire plant. The court ruled that France cannot prohibit the distribution of CBD lawfully produced in another EU member state. The Court stated that public health reasons might allow for some restrictions, but these must be appropriate and proportionate.
The situation in Hungary illustrates the challenges producers face due to complex and inconsistent regulations. In 2020, the Hungarian news portal Telex described how Hungarian CBD businesses were sending hemp flowers to Czechia for extraction, with the resulting CBD material then returning to Hungary or being exported elsewhere.
This solution highlights the fundamental regulatory asymmetry where tasks that are difficult or impossible to carry out in Hungary could be moved to a neighboring country with a different regulatory environment.
How Regulation Shapes Cannabis Supply Chains
While these cases focus specifically on CBD, their implications also extend to other cannabinoids and THC-rich cannabis flowers. This highlights a key conflict within the European cannabis market: national governments’ regulations—shaped by their unique public health, criminal justice, and market policy choices—can come into conflict with EU internal market rules, including the free movement of goods.
A company that views Europe as a single, unified cannabis market may, through bitter experience, come to realize that the opposite is true. For example, a medical cannabis manufacturer must understand each country’s pharmaceutical, controlled substance, and import/distribution regulations to operate successfully. Without this knowledge, it is impossible to accurately understand the interactions that arise when markets with different drug policy backgrounds converge.
The fact that European countries have differing cannabis policies is not a problem in itself, especially if these regulations are consistent with relevant EU legislation and objectives. The real challenge for international companies is the lack of an appropriate framework that would facilitate effective operations across diverse legal environments.
The absence of such a framework, of course, does not prevent people and companies from crossing borders. Patients will still bring their own medications, while companies may reorganize supply chains and navigate the practical application of different rules.
Looking Beyond National Models
It is promising that EUDA is developing a cannabis policy toolkit for 2026–2027 that will support the planning, implementation, monitoring, and evaluation of national cannabis policies. Given the fragmented regulatory landscape in Europe, this step is essential. Yet national evaluations may not capture the full picture, especially when it comes to the ways different systems interact with each other.
The European Union therefore needs to develop a better understanding of how its Member States’ cannabis policies affect one another. European cannabis markets are inevitably becoming interconnected even before their regulatory systems become compatible with one another. That gap will grow harder to overlook as more countries change their cannabis policies.
Frequently Asked Questions
Why does Europe have a fragmented cannabis market?
Countries have adopted different approaches to medical cannabis, adult use, home cultivation, and CBD. As Kardos explains, those national systems were not necessarily designed to work together when patients, goods, or businesses cross borders.
How do different national rules affect cannabis businesses?
A company may source materials in one country, process them in another, and serve patients in a third. The article explains why businesses must understand each country’s pharmaceutical, controlled-substance, and import and distribution requirements.
What cross-border challenges do patients face?
The article highlights uncertainty over whether a medical cannabis prescription from a patient’s home country will be recognized abroad. Differing national frameworks can make cross-border travel with prescribed cannabis complicated.
Why does Kardos call for looking beyond national policy models?
He argues that evaluating individual countries’ policies cannot fully explain how those systems interact. His central concern is the growing gap between interconnected European cannabis markets and regulatory systems that remain incompatible.
